🔎 Trials Near Me

Home › Mesothelioma › Texas › Houston

Pag-aaral pangklinika para sa Mesothelioma sa Houston, TX

Isang pag-aaral para sa Mesothelioma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Houston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

SW-682 in Advanced Solid Tumors

Nagre-recruitPhase 1
  • U.T. MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06251310

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • Baylor St Lukes, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05932199

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Nagre-recruitPhase 1
  • MD Anderson, Houston
  • NEXT Oncology Houston, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07277413

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07705334

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

Nagre-recruitPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04969315

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Nagre-recruitPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05732831

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Nagre-recruitPhase 1
  • MDACC, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05245500

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT06710756

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT05568680

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06362369

A Study of VET3-TGI in Patients With Solid Tumors

Nagre-recruitPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 7, 2026 · NCT06444815

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT04665206

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Nagre-recruitPhase 1/2
  • The University of Texas MD Anderson Cancer Center (site 127), Houston
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Dis 11, 2025 · NCT03556228

A Study of NX-1607 in Adults With Advanced Malignancies

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT05107674

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 9, 2024 · NCT06452160

Pag-aaral para sa Mesothelioma sa ibang lungsod

Iba pang pag-aaral sa Houston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.